FDA Drug Compounding Enforcement Continues With Teregen Labs Citation
This article was originally published in The Pink Sheet Daily
Executive Summary
The Gentere subsidiary distributes compounded drug products for those commercially available and without valid prescriptions, an FDA warning letter states. The agency also cites the firm for cGMP violations.
You may also be interested in...
FDA Cites Respi Care As Part Of Pharmacy Compounding Enforcement
The agency issues its second “warning letter” in a month citing a pharmacy’s compounding operations as comparable to that of a drug manufacturer. The agency also notes cGMP violations observed during an inspection of Respi Care’s facility in Puerto Rico.
FDA Cites Respi Care As Part Of Pharmacy Compounding Enforcement
The agency issues its second “warning letter” in a month citing a pharmacy’s compounding operations as comparable to that of a drug manufacturer. The agency also notes cGMP violations observed during an inspection of Respi Care’s facility in Puerto Rico.
Pharmacy's Compounding Resembles Rx Manufacturing Operation, FDA Says
FDA "warning letter" states that Lincare and Reliant Pharmacy produce "essentially copies of commercially available drugs" without documented patient-specific medical need. This practice goes beyond the scope of traditional compounding, the letter states.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: